Claims for Patent: 8,357,690

Summary for Patent: 8,357,690

Title:	Methods of treatment using combination therapy
Abstract:	Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.
Inventor(s):	Robert C. Armstrong, Barbara A. Belli
Assignee:	Ambit Bioscience Corp
Application Number:	US12/730,097
Patent Claims:	1. A method of treating a proliferative disease in a mammal, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of: (a) a compound of structural formula A or a salt thereof, and (b) a second agent selected from a nucleoside analog, wherein the nucleoside analog is a neoplastic cell antimetabolite; an anthracycline and a topoisomerase inhibitor, or a combination thereof. 2. A method of treating a proliferative disease in a mammal, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of a compound of Formula A or a pharmaceutically acceptable salt thereof, and a therapeutically acceptable dose of a second agent selected from an anthracycline and a topoisomerase inhibitor. 3. A method of treating a hematological neoplastic disease comprising co-administering to a patient in need thereof a therapeutically effective amount of (a) a nucleoside analog, wherein the nucleoside analog is a neoplastic cell antimetabolite; and (b) a compound of structural formula A: or a salt thereof. 4. The method of claim 1, wherein the compound of formula A or a pharmaceutically acceptable salt thereof is administered in a dose of at least 12 mg per day. 5. The method of claim 1, wherein the compound of formula A or a pharmaceutically acceptable salt thereof is administered in a dose of about 27 to 1000 mg per day. 6. The method of claim 1, wherein the compound of formula A or a pharmaceutically acceptable salt thereof is administered in a dose of about 40 to 450 mg per day. 7. The method of claim 1, wherein the compound of formula A or a pharmaceutically acceptable salt thereof is administered in a dose of about 12, about 18, about 27, about 40, about 60, about 90, about 135, about 200, or about 450 mg per day. 8. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof, is administered once per day for one week, two weeks, or three weeks. 9. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once per day for fourteen days. 10. The method of claim 1, wherein the second agent is a nucleoside analog. 11. The method of claim 10, wherein the nucleoside analog comprises a phosphate moiety. 12. The method of claim 11, wherein the nucleoside analog is fludarabine phosphate. 13. The method of claim 10, wherein the nucleoside analog does not comprise a phosphate moiety. 14. The method of claim 13, wherein the nucleoside analog is selected from the group consisting of decitabine, azacitidine, clofarabine, cytarabine, cladribine and a combination thereof. 15. The method of claim 10, wherein the nucleoside analog is a DNA methylation inhibitor. 16. The method of claim 15, wherein the nucleoside analog is decitabine, azacitidine, or a combination thereof. 17. The method of claim 1, wherein the second agent is selected from etoposide, cytarabine, clofarabine, idarubicin and daunorubicin, or a combination thereof. 18. The method of claim 17, wherein cytarabine is administered in a dose of about 100 mg/m2/day, 200 mg/m2/day, 750 mg/m2/day, 1 g/m2/day or 3 g/m2/day. 19. The method of claim 18 further comprising co-administering an anthracycline. 20. The method of claim 1, wherein the anthracycline is selected from the group consisting of doxorubicin, daunorubicin, vulrubicin, idarubicin, epirubicin, and a combination thereof. 21. The method of claim 20, wherein daunorubicin is administered in a dose of about 25, 30, 45, or 60 mg/m2/day. 22. The method of claim 17, wherein etoposide is administered in a dose from about 10 mg/m2/day to about 150 mg/m2/day. 23. The method of claim 17, wherein the dose of etoposide is about 35, 50, 100 or 150 mg/m2/day. 24. The method of claim 22, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once a day for one week, two weeks, three weeks, four weeks or five weeks and etoposide is administered once a day for 5 days. 25. The method of claim 22, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once a day for one week, two weeks, three weeks, four weeks or five weeks and etoposide is administered once a day on days 1, 3, and 5. 26. The method of claim 17, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once a day for one week, two weeks, three weeks, four weeks or five weeks and cytarabine is administered once a day for 7 days. 27. The method of claim 17, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once a day for one week, two weeks, three weeks, four weeks or five weeks and cytarabine is administered once a day on days 1, 3 and 5. 28. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once a day for one week, two weeks, three weeks, four weeks or five weeks and daunorubicin is administered once a day on days 1, 2 and 3. 29. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered once a day for one week, two weeks, three weeks, four weeks or five weeks, cytarabine is administered once a day for 7 days and daunorubicin is administered once a day on days 1, 2 and 3. 30. The method of claim 1, wherein the proliferative disease is cancer. 31. The method of claim 29, wherein the cancer is a leukemia. 32. The method of claim 31, wherein the leukemia is an acute leukemia. 33. The method of claim 31, wherein the leukemia is acute myeloid leukemia. 34. The method of claim 31, wherein the leukemia is promyelocytic leukemia. 35. The method of claim 31, wherein the leukemia is acute lymphoblastic leukemia. 36. The method of claim 31, wherein the leukemia is positive for the FLT3-ITD mutation. 37. The method of claim 31, wherein the leukemia is relapsed or refractory. 38. The method of claim 31, wherein the leukemia is a drug-resistant leukemia. 39. The method of claim 38, wherein the drug-resistant leukemia is resistant to a FLT3 kinase inhibitor. 40. The method of claim 30, wherein the cancer is a solid tumor. 41. The method of claim 40, wherein the cancer is a bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, or hematologic malignancy. 42. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered orally. 43. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered parenterally. 44. The method of claim 1, wherein the compound of formula A, or a pharmaceutically acceptable salt thereof is administered intravenously.